Sonnet BioTherapeutics Holdings, Inc.
DelistedCIK 1106838fmd_1WTW4RTA59ZTBD7EWH7XKYX34YManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Oct 01, 2009 to Sep 30, 2025, 62 periods
| Line item | FY2018 | FY2019 | FY2019 | FY2020 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 41 | 31 | – | 30 | – | 0 | 0 | 0 | 0 | 1 |
| Net interest income | – | – | (0) | – | 0 | – | – | – | – | – |
| Commissions and fees | – | – | – | – | – | – | – | – | – | – |
| Realized investment gains (losses) | – | – | – | – | – | – | – | – | – | – |
| Research and development | – | – | 2 | – | 10 | 17 | 21 | 12 | 6 | 8 |
| Total operating expenses | 23 | 18 | – | – | 24 | 26 | 30 | 19 | 12 | 17 |
| Compensation and benefits | – | – | – | – | – | – | – | – | 1 | 2 |
| Operating income | (5) | (5) | – | – | (24) | (25) | (30) | (19) | (12) | (16) |
| Interest expense | 3 | 3 | – | 1 | – | – | – | – | – | – |
| Interest and investment income | 0 | (0) | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (3) | (3) | – | (1) | – | – | – | – | – | – |
| Income before taxes | (8) | (8) | – | (17) | – | – | – | – | (7) | (16) |
| Income tax expense | (1) | (1) | – | 0 | – | – | – | – | – | 0 |
| Net income from continuing operations | (7) | (7) | – | (17) | – | – | – | – | – | (16) |
| Net income | (7) | (7) | – | – | (24) | (25) | (30) | (19) | (7) | (16) |
| Net income to common shareholders | (7) | (7) | – | – | (66) | (25) | – | – | (7) | (16) |